Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Breast Neoplasms, Survival Analysis, Antineoplastic Agents, Therapeutic Uses
Both
Breast Neoplasms, Survival Analysis, Antineoplastic Agents, Therapeutic Uses
Trial Information
Association Between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients With Tamoxifen Treatment
Inclusion Criteria:
- age ≥ 18 years
- Breast cancer patients who underwent surgery
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
The frequency of the genetic polymorphisms of CYP2D6 in breast cancer patients
Safety Issue:
No
Principal Investigator
Byeong-Woo Park, M.D.,ph.D.
Investigator Role:
Study Chair
Investigator Affiliation:
Department of Surgery and Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine
Authority:
Korea: Institutional Review Board
Study ID:
4-2009-0483
NCT ID:
NCT01169792
Start Date:
Completion Date:
Related Keywords:
- Breast Neoplasms
- Survival Analysis
- Antineoplastic Agents
- Therapeutic Uses
- Tamoxifen
- Cytochrome P-450 CYP2D6
- Polymorphism
- Single nucleotide
- Antineoplastic Agents, Hormonal
- Breast Neoplasms
- Neoplasms
Name | Location |
|---|
